Zilganersen is an investigational antisense oligonucleotide designed to block the product of excess GFAP caused by mutations in the GFAP gene.

ST-503 is a one-time dose, investigational epigenetic regulator that specifically targets and silences the SCN9A gene.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for baxdrostat for the add-on treatment of uncontrolled or treatment resistant hypertension in ...

HealthDay News — A growing list of pots and pans is now considered unsafe, and the US Food and Drug Administration (FDA) is urging people to check their kitchens and get rid of them right away. In a ...

While the International Agency for Research on Cancer labels talc that may contain asbestos as “probably carcinogenic,” the mineral continues to fall under the FDA’s Generally Recognized As Safe (GRAS ...

Earlier this year, Abraham urged Louisiana Senator Dr Bill Cassidy, a gastroenterologist who strongly supports childhood vaccines, to confirm Robert F. Kennedy Jr. as health secretary. The 2 men later ...

If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.

HealthDay News — Women with persistent thyroid hormone imbalance across pregnancy may have an increased risk of having children with autism spectrum disorder (ASD), according to a study published ...

HealthDay News — Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), according to a living clinical practice guideline issued by ...

HealthDay News — Obstructive sleep apnea (OSA) seems to be an independent risk factor for development of Parkinson disease, and early use of continuous positive airway pressure (CPAP) could modify the ...

Tinlarebant is a novel oral therapy designed to reduce the build-up of bisretinoids, vitamin A-based toxins that lead to retinal complications in STGD1.

74,311 individuals had been enrolled in trials classified as active and not recruiting at time of funding termination.